Simon Bedard, CEO at Exit Advisory Group, an advisory firm that focuses on mergers & acquisitions, exit strategies and business valuations. “Every entrepreneur exits. It’s one of the few ...
In January, Pfizer said it was planning to axe almost its entire neuroscience R&D programmes with around 300 job losses, but decided to retain a couple of late-stage projects including pain drug ...